A phase 1/2 trial of APL-5125 in colorectal cancer, biliary tract cancer, appendiceal cancer and pseudomyxoma peritonei, pancreatic ductal adenocarcinoma, gastric & gastro-oesophageal junction cancer and endometrial cancer, run by Apollo Therapeutics Ltd, active and no longer recruiting.
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06399757 by Apollo Therapeutics Ltd, with 100 participants enrolled, started 2024-06-18 and due to reach its primary completion in 2027-04. Interventions recorded: APL-5125.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.